[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
Borja
J
J
Departamento de Medicina. Pharmacia & Upjohn, S.A. Sant Cugat del Vallés. Barcelona. javier.borja@eu.pnu.com
Olivella
P
P
D000789:Angina, Unstable / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016001:Confidence Intervals; D017985:Dalteparin / Q000008:administration & dosage / Q000627:therapeutic use; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D004562:Electrocardiography; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D017762:Nadroparin / Q000008:administration & dosage / Q000627:therapeutic use; D016017:Odds Ratio; D010919:Placebos; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012306:Risk; D013997:Time Factors
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; D010919:Placebos; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D001241:Aspirin; D017985:Dalteparin